NTLA vs. CLDX, MYGN, NEOG, QDEL, EDIT, CRSP, CLLS, SGMO, LNTH, and JANX
Should you be buying Intellia Therapeutics stock or one of its competitors? The main competitors of Intellia Therapeutics include Celldex Therapeutics (CLDX), Myriad Genetics (MYGN), Neogen (NEOG), QuidelOrtho (QDEL), Editas Medicine (EDIT), CRISPR Therapeutics (CRSP), Cellectis (CLLS), Sangamo Therapeutics (SGMO), Lantheus (LNTH), and Janux Therapeutics (JANX). These companies are all part of the "medical" sector.
Celldex Therapeutics (NASDAQ:CLDX) and Intellia Therapeutics (NASDAQ:NTLA) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations, valuation and community ranking.
Celldex Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Celldex Therapeutics presently has a consensus target price of $66.00, indicating a potential upside of 72.73%. Intellia Therapeutics has a consensus target price of $66.77, indicating a potential upside of 154.65%. Given Celldex Therapeutics' higher possible upside, analysts plainly believe Intellia Therapeutics is more favorable than Celldex Therapeutics.
Intellia Therapeutics has a net margin of -893.34% compared to Intellia Therapeutics' net margin of -2,385.57%. Intellia Therapeutics' return on equity of -29.55% beat Celldex Therapeutics' return on equity.
Celldex Therapeutics received 181 more outperform votes than Intellia Therapeutics when rated by MarketBeat users. Likewise, 74.91% of users gave Celldex Therapeutics an outperform vote while only 69.37% of users gave Intellia Therapeutics an outperform vote.
88.8% of Intellia Therapeutics shares are held by institutional investors. 3.7% of Celldex Therapeutics shares are held by company insiders. Comparatively, 3.0% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Intellia Therapeutics had 1 more articles in the media than Celldex Therapeutics. MarketBeat recorded 6 mentions for Intellia Therapeutics and 5 mentions for Celldex Therapeutics. Intellia Therapeutics' average media sentiment score of 0.40 beat Celldex Therapeutics' score of 0.28 indicating that Celldex Therapeutics is being referred to more favorably in the media.
Celldex Therapeutics has a beta of 1.6, suggesting that its share price is 60% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.
Summary
Celldex Therapeutics beats Intellia Therapeutics on 10 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding NTLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Intellia Therapeutics Competitors List
Related Companies and Tools
